Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HarrowHROW +5.36%80 Operating Margin % is -15.58% as of Jun. 2026. GuruFocus rates HROW with a GF Score™ of 80/100 and a GF Value™ of $42.00 (Fairly Valued). The stock has 4 warning signs investors should review. Among 957 Drug Manufacturers companies, Harrow ranks worse than 71.16% on this metric.
Operating Margin % is calculated as Operating Income divided by its Revenue. Harrow's Operating Income for the
three
months ended in Jun. 2026 was $-11.0 Mil. Harrow's Revenue for the
three
months ended in Jun. 2026 was $70.7 Mil. Therefore, Harrow's Operating Margin % for the quarter that ended in Jun. 2026 was -15.58%.
Good Sign:
Harrow Inc operating margin is expanding. Margin expansion is usually a good sign.
The historical rank and industry rank for Harrow's Operating Margin % or its related term are showing as below:
HROW'
s Operating Margin % Range Over the Past 10 Years
Min: -78.12 Med: 1.08 Max: 11.21
Current: -1
HROW's Operating Margin % is ranked worse than 71.16% of 957
companies
in the Drug Manufacturers industry
Industry Median: 7.29
vs HROW: -1.00
Harrow's 5-Year Average Operating Margin % Growth Rate was 34.70% per year.
Harrow's Operating Income for the
three
months ended in Jun. 2026 was $-11.0 Mil.
Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.7 Mil.
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Harrow Operating Margin % Related Terms
Harrow Operating Margin % Historical Data
* Premium members only.
The historical data trend for Harrow's Operating Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HROW vs XERS, PRGO, PAHC: Operating Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Harrow's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Harrow Operating Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Harrow's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Harrow's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Harrow's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Harrow (HROW) has a Operating Margin % of -15.58% as of Jun. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Harrow and its competitors. According to the industry distribution chart, Harrow ranks #681 out of 957 companies in the Drug Manufacturers industry, placing it in the top 71.2%.
Is Harrow's Operating Margin % too high?
Harrow's current Operating Margin % is -15.58%. Based on the distribution chart, Harrow ranks #681 out of 957 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Harrow has a GF Score™ of 80/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Harrow's Operating Margin % compare to XERS and PRGO?
According to the Drug Manufacturers industry distribution chart, Harrow ranks #681 out of 957 companies for Operating Margin %. This places Harrow in the lower half of its industry. The industry median Operating Margin % is 7.29. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.29, based on 957 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Harrow and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Harrow's current Operating Margin % is -15.58%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harrow stock overvalued right now?
Based on GuruFocus' analysis, Harrow (HROW) is currently considered Fairly Valued. The stock's GF Value™ is $42.00, compared to a current price of $41.63 — trading 0.9% below its estimated fair value. The current Operating Margin % is -15.58%. Harrow's overall GF Score™ is 80/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Harrow (HROW), the current Operating Margin % is -15.58% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Harrow (HROW) Overvalued in 2026?
Based on GuruFocus' analysis, Harrow stock appears to be undervalued.
The current stock price of $41.63 is trading 0.9% below its estimated GF Value™ of $42.00.
GuruFocus considers Harrow to be Fairly Valued.
Key valuation signals for HROW:
Operating Margin %: -15.58%
GF Value™: $42.00 vs. price of $41.63 (0.9% below fair value)
No single metric tells the full story. See the HROW stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company partners with U.S. eyecare professionals to develop products used to manage ophthalmic conditions affecting both the front and back of the eye, such as dry eye disease, cataracts, refractive errors, glaucoma, etc. Its portfolio of branded ophthalmic pharmaceuticals includes Iheezo, Vevye, Byooviz Opuviz, Natacyn, Maxitrol, Maxidex, etc. Additionally, the company's development pipeline comprises candidates like MELT-300, H-N08, CR-01, and MELT-210, being developed to address unmet needs in eye care and selected adjacent markets. Its reportable segments are: Branded, which derives maximum revenue, and ImprimisRx.
80GF Score
Get the complete analysis for HROW
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HROW has been successfully added to your 
